New Medicine for Breast Cancer
Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment
['FUNDING_U01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-11137790
Researchers are working to create a new medicine that targets a specific enzyme in breast cancer cells, aiming to stop their growth.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-11137790 on ClinicalTrials.gov |
What this research studies
This project focuses on developing a new type of drug that can block the activity of an enzyme called exonuclease 1 (EXO1), which is important for DNA repair in cells. Cancer cells often have more DNA damage and rely heavily on EXO1 to survive, making it a good target for treatment. Scientists will use advanced screening methods to find potential drug candidates and then refine them to create a powerful and specific medicine. The goal is to create a new tool for research and a starting point for a future breast cancer drug.
Who could benefit from this research
Good fit: This early-stage research is for patients with breast cancer, particularly those whose tumors might be vulnerable to targeting DNA repair pathways.
Not a fit: Patients without breast cancer or those whose cancer does not depend on the EXO1 enzyme for survival may not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to a completely new medication for breast cancer, especially for patients whose tumors rely on this specific DNA repair pathway.
How similar studies have performed: This approach is novel as there are currently no known specific small molecule inhibitors for the EXO1 enzyme.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHEN, BINGHUI — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: SHEN, BINGHUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.